Literature DB >> 18825549

Injecting risk behaviour and related harm among men who use performance- and image-enhancing drugs.

Briony Larance1, Louisa Degenhardt, Jan Copeland, Paul Dillon.   

Abstract

INTRODUCTION AND AIMS: Performance- and image-enhancing drugs have the potential to be a significant public health issue. Detailed data on PIEDs injection are difficult to obtain because of the illicit and unsupervised way in which many PIEDs are used, and the hidden nature of the group. Our study examines the patterns of use, risk behaviours and related harm associated with PIEDs injection. We also report the ways in which PIEDs users currently seek injecting equipment and harm-reduction advice. DESIGN AND
METHOD: Data were obtained via a structured questionnaire administered in face-to-face interviews with 60 men who used PIEDs (primarily anabolic androgenic steroids) for non-medical purposes.
RESULTS: Although the rates of needle sharing were low (5%), the men more frequently reported re-use of needles/equipment, injecting from a shared container (bladders, vials, etc.), injecting other illicit drugs, injecting insulin and targeting small muscle groups. Self-reports of being hepatitis C antibody positive were associated with lifetime use of heroin and injection of other illicit drugs. All HIV positive participants were gay/bisexual men. Participants reported a range of other injection-related injuries and diseases such as fevers, scarring and abscesses. 'Risky' injectors (38% of participants) were more likely to initiate PIEDs use at a younger age, use PIEDs in a larger number of cycles per year and report involvement in a violent/aggressive incident than 'low risk' injectors and report involvement in a violent/aggressive incident than 'low risk' injectors. Participants mainly reported seeking information about PIEDs from internet sites (62%) and friends (55%).
CONCLUSIONS: An over-reliance on personal networks and internet forums limits this groups' access to objective harm reduction advice and primary care services. Targeted, PIEDs-specific interventions are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825549     DOI: 10.1080/09595230802392568

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  11 in total

Review 1.  Comprehensive clinical care for men who have sex with men: an integrated approach.

Authors:  Kenneth H Mayer; Linda-Gail Bekker; Ron Stall; Andrew E Grulich; Grant Colfax; Javier R Lama
Journal:  Lancet       Date:  2012-07-20       Impact factor: 79.321

2.  The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: current best estimates.

Authors:  Harrison G Pope; Gen Kanayama; Alison Athey; Erin Ryan; James I Hudson; Aaron Baggish
Journal:  Am J Addict       Date:  2013-09-20

Review 3.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 4.  Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.

Authors:  Lindsey J Anderson; Jamie M Tamayose; Jose M Garcia
Journal:  Mol Cell Endocrinol       Date:  2017-06-09       Impact factor: 4.102

5.  Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis.

Authors:  Julio Mario Xerfan Amaral; Andreas Kimergård; Paolo Deluca
Journal:  BMJ Open       Date:  2022-07-04       Impact factor: 3.006

Review 6.  Anabolic-androgenic steroid dependence: an emerging disorder.

Authors:  Gen Kanayama; Kirk J Brower; Ruth I Wood; James I Hudson; Harrison G Pope
Journal:  Addiction       Date:  2009-12       Impact factor: 6.526

7.  Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking.

Authors:  V D Hope; J McVeigh; A Marongiu; M Evans-Brown; J Smith; A Kimergård; J V Parry; F Ncube
Journal:  Epidemiol Infect       Date:  2014-04-08       Impact factor: 4.434

8.  Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study.

Authors:  Andreas Kimergård; Jim McVeigh
Journal:  Harm Reduct J       Date:  2014-07-02

Review 9.  Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis.

Authors:  Dominic Sagoe; Jim McVeigh; Astrid Bjørnebekk; Marie-Stella Essilfie; Cecilie Schou Andreassen; Ståle Pallesen
Journal:  Subst Abuse Treat Prev Policy       Date:  2015-03-15

10.  Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study.

Authors:  Vivian D Hope; Jim McVeigh; Andrea Marongiu; Michael Evans-Brown; Josie Smith; Andreas Kimergård; Sara Croxford; Caryl M Beynon; John V Parry; Mark A Bellis; Fortune Ncube
Journal:  BMJ Open       Date:  2013-09-12       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.